Tầm soát biến cố tăng kali máu liên quan đến thuốc thông qua kết quả xét nghiệm cận lâm sàng tại Bệnh viện Trung ương Quân đội 108

Abstract

Objective: To detect hyperkalemia in hospitalized patients base on laboratory database and to describe the characteristics of cases of drug-associated hyperkalemia defined according to the WHO-UCM causality assessment system. Subject and method: All blood potassium tests of inpatients at 108 Military Central Hospital, 2019.  Method: Retrospective study, data were collected from medical records. Pseudohyperkalemia cases and patients dialyzed for end-stage renal disease was excluded. Result: Of 136 hyperkalemia cases (mean age: 65.8 ± 17.6 years), 76 (73.5%) were classified as drug-associated. Renal impairment (eGFR < 60mL/min/1.73m²) is observed in most cases (89.7%). Most of patients experienced minor hyperkalemia (52.2%) while serious and life-threthening hyperkalemia occurred in 24.2%. Drugs for peptic ulcer and gastro-oesophageal reflux disease, aldosterone antagonists and potassium supplements were considered to be a medication predominantly induced hyperkalemia. 88.2% of patients were treated, mainly with furosemid and calcium clorid. Conclusion: Results of this study suggested the necessity to monitor regularly potassium levels of the patients treated with potassium-increasing medications.